|
https://www.thedailybeast.com/two-moderna-execs-sold-dollar30-million-in-company-stocks-after-hyping-promising-vaccine-results -
Two of biotech company Moderna’s top executives dumped millions in company stocks just as the value peaked by 30 percent on news of early success in clinical trials for a COVID-19 vaccine. But right before medical reviews suggested that the results weren’t as promising as had been hyped, the company’s chief financial officer and chief medical officer sold off $30 million in company shares through an automated system that reads futures on certain volatile stocks. CNN Business reports that Lorence Kim, Moderna’s CFO, exercised 241,000 options for $3 million on Monday and then quickly sold them for $19.8 million, creating a profit of $16.8 million. Tal Zaks, Moderna’s chief medical officer, spent $1.5 million to exercise options the next day and then immediately sold the shares for $9.77 million, making a hefty profit of $8.2 million. Moderna says that because the sales were executed under a so-called 10b5-1 plan established in advance, they are not suspect. Former Moderna director Moncef Slaoui recently left the company to lead the White House’s vaccine development effort
https://www.cnn.com/2020/06/01/business/moderna-vaccine-stock-sales-invs/index.html - https://www.cnn.com/2020/06/01/business/moderna-vaccine-stock-sales-invs/index.html
New York (CNN Business)Moderna http://www.cnn.com/2020/05/22/investing/moderna-coronavirus-vaccine-stock-sales/index.html - set off a frenzy on Wall Street earlier this month when it announced positive, preliminary results from its coronavirus vaccine trial. As the hype grew, the young biotech company and its leading investor wasted no time capitalizing on the briefly surging stock price. Even as critics accused Moderna of overhyping the http://www.cnn.com/2020/05/18/health/coronavirus-vaccine-moderna-early-results/index.html - results released on May 18 , a series of https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-pricing-public-offering-shares-common-stock-0 - transactions were executed before its share price fizzled over the next week. The timing of those deals, former SEC officials said, appear to be "highly problematic" and should be investigated for potential illegal market manipulation. Just hours after revealing the promising vaccine results, Moderna ( https://money.cnn.com/quote/quote.html?symb=MRNA&source=story_quote_link - MRNA ) sold 17.6 million shares to the public. That share sale, unveiled after the closing bell on May 18, was priced at $76; Moderna traded at just $48 as recently as May 6. The deal instantly raised $1.3 billion. Two of Moderna's top executives also cashed in on the boom at their company, which had suddenly amassed a $29 billion market value https://www.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html - despite the fact it has no marketed products.
https://www.statnews.com/2020/05/19/vaccine-experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/ - https://www.statnews.com/2020/05/19/vaccine-experts-say-moderna-didnt-produce-data-critical-to-assessing-covid-19-vaccine/
Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be https://www.statnews.com/2020/05/18/early-data-show-moderna-covid-19-vaccine-generates-immune-response/ - - stock valuation also surged , hitting $29 billion, an astonishing feat for a company that currently sells zero products. But was there good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be. While Moderna blitzed the media, it revealed very little information — and most of what it did disclose were words, not data. That’s important: If you ask scientists to read a journal article, they will scour data tables, not corporate statements. With science, numbers speak much louder than words.
|